Pfizer faces a risk of losing $15 billion in annual revenue by 2028 due to patent expirations on key drugs (Ebrance, Excandi, Eloquis).
"$15 billion in annual revenue is at risk by 2028 from expiring exclusivity on major drugs like Ebrance, Excandi, and Eloquis."